1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Albumin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
5.1.1.2. Surging utilization of albumin as a food and cosmetic ingredient
5.1.2. Restraints
5.1.2.1. Potential of albumin to cause transmission of infections
5.1.3. Opportunities
5.1.3.1. Ongoing research activities regarding albumin nanoparticles
5.1.3.2. Advancements in albumin production and purification methods
5.1.4. Challenges
5.1.4.1. Stringent regulations associated with albumin manufacturing and quality control
5.2. Market Segmentation Analysis
5.2.1. Source: Consumer shift toward the plant-based albumins due to enhanced sustainability for specific therapeutic purposes.
5.2.2. Type: Enhanced emphasis on the research and development of recombinant albumin as a synthetic protein to promote recombinant DNA technology
5.2.3. Application: Rising focus on vaccine manufacturing and drug delivery applications
5.2.4. End-User: Extensive end-users of the albumin in hospitals and blood banks
5.3. Market Trend Analysis
5.3.1. Medical technology advancements supplemented with robust investment across the Americas
5.3.2. Expanding production coupled with availability of safety regulations to monitor albumin products in APAC region
5.3.3. Significant research activities and government regulatory framework in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Albumin Market, by Source
6.1. Introduction
6.2. Animal Sources
6.3.1. Bovine Serum Albumin
6.3.2. Human Serum Albumin
6.3.3. Ovalbumin
6.3. Plant Sources
7. Albumin Market, by Type
7.1. Introduction
7.2. Non-Recombinant
7.3. Recombinant
8. Albumin Market, by Application
8.1. Introduction
8.2. Cosmetic Ingredient
8.3. Culture Media
8.4. Drug Delivery
8.5. Food Ingredient
8.6. Therapeutic
8.7. Vaccine Ingredient
9. Albumin Market, by End User
9.1. Introduction
9.2. Pharmaceutical & Biotechnology
9.3. Research Institutes
10. Americas Albumin Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Albumin Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Albumin Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Sartorius acquires Albumedix: A player in advanced therapies based on recombinant albumin
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. GC Biopharma inks USD 90mn deal for blood products in Brazil
13.3.2.2. Albumedix Enters into Collaboration Agreement with Cell and Gene Therapy Catapult
13.3.2.3. Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine
13.3.3. New Product Launch & Enhancement
13.3.3.1. American Regent Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)
13.3.4. Investment & Funding
13.3.4.1. Taibang Biologic Group Secures Equity Raising of USD 300 Million
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Grifols Completes Enrollment In Phase 3 Study Of Long-Term Albutein (Albumin-Human Injection) Therapy For Patients With Decompensated Cirrhosis
13.3.5.2. Kedrion’s Global Portfolio Expands To China To Supply Human Albumin
13.3.5.3. SK Plasma to build USD 250m blood products plant in Indonesia
13.3.5.4. Grifols Inaugurates New Albumin Plant At its Expanding Dublin Site
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Aadi Bioscience, Inc.
14.1.2. Agilent Technologies, Inc.
14.1.3. Akron Biotech
14.1.4. Atlantis Bioscience Pte Ltd.
14.1.5. Avantor Inc.
14.1.6. Baxter International Inc.
14.1.7. Becton, Dickinson and Company
14.1.8. Bio Products Laboratory Ltd.
14.1.9. Bio-Rad Laboratories, Inc.
14.1.10. Bio-Techne Corporation
14.1.11. Biogenix Inc. Pvt. Ltd.
14.1.12. Biophyll GmbH
14.1.13. Biorbyt Ltd.
14.1.14. Biowest SAS
14.1.15. Boston BioProducts Inc.
14.1.16. Bristol-Myers Squibb Company
14.1.17. CENTURION PHARMA İlaç Sanayi ve Ticaret A.Ş.
14.1.18. China Biologic Products Holdings, Inc. by Taibang Biologic Group
14.1.19. CSL Limited
14.1.20. Dem İlaç
14.1.21. F. Hoffmann-La Roche AG
14.1.22. GC Biopharma Corp.
14.1.23. Glentham Life Sciences Limited
14.1.24. Grifols SA
14.1.25. InVitria
14.1.26. InVitroCare Inc.
14.1.27. Kedrion S.p.A
14.1.28. Kraeber & Co. GmbH
14.1.29. Lazuline Biotech Private Limited
14.1.30. LGC Science Group Holdings Limited
14.1.31. Merck KGaA
14.1.32. Midas Pharma GmbH
14.1.33. Octapharma AG
14.1.34. Promega Corporation
14.1.35. Prospec-Tany Technogene Ltd.
14.1.36. Rockland Immunochemicals Inc.
14.1.37. Rocky Mountain Biologicals, LLC
14.1.38. Sartorius AG
14.1.39. Serion GmbH
14.1.40. SK Plasma
14.1.41. Takeda Pharmaceuticals Company Limited
14.1.42. Thermo Fisher Scientific Inc.
14.1.43. Ventria Bioscience Inc.
14.1.44. VitroScient
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing